<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01229098</url>
  </required_header>
  <id_info>
    <org_study_id>LEO 80185-G24</org_study_id>
    <nct_id>NCT01229098</nct_id>
  </id_info>
  <brief_title>Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris</brief_title>
  <official_title>A Phase 2 Maximal Use Systemic Exposure Study Evaluating the Safety and Efficacy of Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Gel Applied Once Daily in Subjects With Extensive Psoriasis Vulgaris on the Scalp and Non-scalp Regions of the Body (Trunk and/or Limbs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of once daily use of LEO 80185 gel on the
      hypothalamic-pituitary-adrenal (HPA) axis and calcium metabolism in subjects with extensive
      psoriasis vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>Subjects with serum cortisol concentration of ≤18 mcg/dl at 30 minutes after ACTH-challenge [ Time Frame: Week 4 and week 8 ] [ Designated as safety issue: Yes ]
Change in albumin-corrected serum calcium from baseline [ Time Frame: Week 4 and week 8 ] [ Designated as safety issue: Yes ]
Change in 24-hour urinary calcium excretion from baseline [ Time Frame: Week 4 and week 8 ] [ Designated as safety issue: Yes ]
Change in urinary calcium:creatinine ratio from baseline [ Time Frame: Week 4 and week 8 ] [ Designated as safety issue: Yes ]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>Subjects with &quot;Controlled disease&quot; (i.e., &quot;Clear&quot; or &quot;Almost clear&quot;) according to the investigator's global assessment of disease severity [ Time Frame: Weeks 2, 4, 8 ] [ Designated as safety issue: No ]
Pharmacokinetic parameters for calcipotriol, betamethasone dipropionate and any metabolites.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 80185</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)</intervention_name>
    <description>LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) Topical suspension applied once daily for up to 8 weeks</description>
    <arm_group_label>LEO 80185</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated informed consent obtained following receipt of verbal and written
             information about the study prior to any trial related activities (including any
             wash-out period).

          2. Age 18 years or above.

          3. Either sex.

          4. Any race or ethnicity.

          5. Attending a hospital out-subject clinic or the private practice of a dermatologist for
             treatment of psoriasis vulgaris.

          6. Clinical diagnosis of psoriasis vulgaris involving non scalp regions of the body
             (trunk and/or limbs) with or without involvement of the scalp.

          7. At SV2 and Day 0 (Visit 1) a clinical diagnosis of psoriasis vulgaris which is:

               -  amenable to topical treatment with a maximum of 100 g of study medication per
                  week, and

               -  of an extent of between 15 and 30% of the body surface area (BSA) excluding
                  psoriasis on the face, genitals or skin folds.

               -  a disease severity on the trunk and/or limbs graded as at least moderate
                  according to the investigator's global assessment (IGA)

          8. Subjects with normal HPA axis function at SV2 including a serum cortisol concentration
             above 5 mcg/dL before ACTH challenge test and above 18 mcg/dL 30 minutes after ACTH
             challenge test.

          9. Albumin-corrected serum calcium, below the upper reference limit at SV2.

         10. Females of child-bearing potential must have a negative urine pregnancy test result at
             baseline Visit SV2 and must agree to use a highly effective method of contraception
             during the study. Highly effective methods are defined as ones which results in a low
             failure rate (less than 1% per year) such as progestin-only formulations (implants,
             injectables), some intra-uterine devices, or vasectomised partner. Subjects must have
             used the contraceptive method continuously for at least 1 month prior to the pregnancy
             test and must continue using the contraceptive method for at least 1 week after the
             last application of study medication (or until study visit FU2 if applicable). A
             female is defined as not of child-bearing potential if she is postmenopausal (12
             months with no menses without an alternative medical cause), or surgically sterile
             (tubal ligation/section, hysterectomy or bilateral ovariectomy).

         11. Able to communicate with the investigator and understand and comply with the
             requirements of the study.

             Exclusion Criteria:

         12. A history of serious allergy, allergic asthma or serious allergic skin rash

         13. Known or suspected hypersensitivity to any medication (including
             ACTH/cosyntropin/tetracosactide) or to any component of the LEO 80185 gel or
             CORTROSYN.

         14. Systemic treatment with corticosteroids (including inhaled and nasal steroids) within
             12 weeks prior to SV2 and during the study.

         15. Systemic treatment with biological therapies (marketed or not marketed), with a
             possible effect on psoriasis vulgaris within the following time period prior to Day 0
             (Visit 1) and during the study:

               -  etanercept - within 4 weeks prior to Visit 1

               -  adalimumab, alefacept, infliximab -within 2 months prior to Visit 1

               -  ustekinumab, briakinumab - within 4 months prior to Visit 1

               -  experimental products - within 4 weeks/5 half-lives (whichever is longer) prior
                  to Visit 1

         16. Systemic treatment with therapies other than biologicals, with a possible effect on
             psoriasis vulgaris (e.g., retinoids, methotrexate, immunosuppressants) within 4 weeks
             prior to Visit 1 (Day 0) or during the study.

         17. PUVA or Grenz ray therapy within 4 weeks prior to Visit 1 (Day 0) or during the study

         18. UVB therapy within 2 weeks prior to Visit 1 (Day 0) or during the study.

         19. Topical treatment with corticosteroids or vitamin D analogues (calcipotriol,
             calcitriol or tacalcitol) on any body location within 2 weeks prior to SV2 or during
             the study.

         20. Any topical treatment of psoriasis vulgaris on the scalp or trunk and/or limbs (except
             for emollients and non-steroid medicated shampoos) within 2 weeks prior to Visit 1
             (Day 0) or during the study.

         21. Oral calcium supplements, vitamin D supplements, antacids, thiazide and/or loop
             diuretics, antiepileptics, diphosphonates or calcitonin within 4 weeks prior to SV2
             and during the study. Note: Stable doses of oral vitamin D supplementation ≤400 IU/day
             is permitted provided there are no dose adjustments during the study period.

         22. Planned initiation of, or changes to, concomitant medication that could affect
             psoriasis vulgaris (e.g., betablockers, antimalarials, lithium, ACE inhibitors) during
             the study.

         23. Planned excessive exposure of treated areas to either natural or artificial sunlight
             (e.g. sunlamps etc.) during the study that may affect the psoriasis vulgaris.

         24. Oestrogen therapy (including contraceptives) or any other medication known to affect
             cortisol levels or HPA axis integrity within 4 weeks prior to SV2 or during the study.

         25. Cytochrome P450 3A4 (CYP 3A4) inducers (e.g., barbiturates, phenytoin, rifampicin)
             within 4 weeks prior to SV2 or during the study.

         26. Systemic or topical cytochrome P450 3A4 (CYP 3A4) inhibitors (e.g., ketoconazole,
             itraconazole, metronidazole) within 4 weeks prior to SV2 or during the study. Topical
             ketoconazole within 2 weeks prior to SV2.

         27. Hypoglycaemic sulfonamides within 4 weeks prior to the SV2 or during the study.

         28. Antidepressant medications within 4 weeks prior to SV2 or during the study.

         29. Not following nocturnal sleep patterns (e.g. night shift workers are excluded).

         30. Known or suspected endocrine disorder that may affect the results of the ACTH
             challenge test.

         31. Clinical signs or symptoms of Cushing's disease or Addison's disease.

         32. Known or suspected diabetes mellitus.

         33. Known or suspected cardiac disorders associated with abnormal QT intervals or rhythm
             disturbances including clinically significant bradycardia or tachycardia.

         34. Known or suspected severe renal insufficiency or severe hepatic disorders.

         35. Known or suspected disorders of calcium metabolism associated with hypercalcaemia.

         36. Any clinically significant abnormality following review of screening laboratory tests
             (blood and spot urine samples), physical examination or blood pressure/heart rate
             measurement performed at SV2.

         37. Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis.

         38. Any of the following conditions present on the study treatment areas: viral (e.g.,
             herpes or varicella) lesions of the skin, fungal and bacterial skin infections,
             parasitic infections, skin manifestations in relation to syphilis or tuberculosis,
             rosacea, acne vulgaris, acne rosacea, atrophic skin, striae atrophicae, fragility of
             skin veins, ichthyosis, ulcers and wounds.

         39. Other inflammatory skin diseases that may confound the evaluation of psoriasis
             vulgaris (e.g. seborrhoeic dermatitis, contact dermatitis and cutaneous mycosis).

         40. Current participation in any other interventional clinical trial.

         41. Previously enrolled in this trial (with the exception of subjects excluded due to
             hypocalcaemia prior to implementation of Consolidated Clinical Study Protocol 2).

         42. Received any non-marketed drug substance (i.e., an agent which has not yet been made
             available for clinical use following registration) within 4 weeks or 5 half-lives
             (whichever is longer) prior to SV1.

         43. Known or suspected of not being able to comply with the trial protocol (e.g.,
             alcoholism, drug dependency or psychotic state).

         44. Females who are pregnant, have a positive urine pregnancy test at baseline Visit SV2,
             or are breast-feeding. Females of child-bearing potential and wishing to become
             pregnant during the study or not using an adequate method of contraception during the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shane Silver, MB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermadvances Research, 203 Edmonton Street, Winnipeg, Manitoba R3C 1R4 Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winnipeg Clinic</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermadvances Research</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 1R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpha Clinical Research Centre</name>
      <address>
        <city>Saint John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 4S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newlab Clinical Research</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1C 2H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Canada Cutaneous Research Associates Ltd.</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermsearch</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5X 2P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cosmetic and Laser Surgery</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Co-Medica Research Network Inc.</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1E 3C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oshawa Clinic</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H 1B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2010</study_first_submitted>
  <study_first_submitted_qc>October 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2010</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

